VCs sell drug maker for up to $935m
Walden International and a number of other VCs will exit from their nearly decade-long investment in cancer drug maker Plexxikon after Japan’s third largest drug maker, Daiichi Sankyo, announced its acquisition of the Berkeley, California-based company.
The terms of the deal will see shareholders receive a one-time payment of about $805 million and up to another $130 million upon the completion of some milestones, namely if Plexxikon's most advanced drug,...
More on North Asia
Latest News
Asian GPs slow implementation of ESG policies - survey
Asia-based private equity firms are assigning more dedicated resources to environment, social, and governance (ESG) programmes, but policy changes have slowed in the past 12 months, in part due to concerns raised internally and by LPs, according to a...
Singapore fintech start-up LXA gets $10m seed round
New Enterprise Associates (NEA) has led a USD 10m seed round for Singapore’s LXA, a financial technology start-up launched by a former Asia senior executive at The Blackstone Group.
India's InCred announces $60m round, claims unicorn status
Indian non-bank lender InCred Financial Services said it has received INR 5bn (USD 60m) at a valuation of at least USD 1bn from unnamed investors including “a global private equity fund.”
Insight leads $50m round for Australia's Roller
Insight Partners has led a USD 50m round for Australia’s Roller, a venue management software provider specializing in family fun parks.